SOURCE: Barrier Therapeutics, Inc.

February 22, 2007 16:05 ET

Barrier Therapeutics to Present at the SIGnificant Investment Options in Healthcare Conference

PRINCETON, NJ -- (MARKET WIRE) -- February 22, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Dr. Geert Cauwenbergh, Chief Executive Officer, is scheduled to provide a company update at the SIGnificant Investment Options in Healthcare Conference.

The conference will be held at the Omni Berkshire Place in New York, NY on March 1, 2007. Barrier Therapeutics is scheduled to present on Thursday, at 3:00 p.m. EST (12:00 p.m. PST).

The presentation will be available live via a webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: An archive of the presentation will be available for replay for 90 days.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including acne, psoriasis, onychomycosis and other fungal infections such as tinea versicolor. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at:

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne VanLent